熱門資訊> 正文

Capricor Therapeutics公司2025年第三季度盈利预览

2025-11-08 06:35

Capri Holdings Limited(CPRI) 0
Capricor治療(CAPR) 0

Capricor Therapeutics, Inc. (CAPR) is scheduled to announce Q3 earnings results on Monday, November 10th, after market close.
The consensus EPS Estimate is -$0.54 and the consensus Revenue Estimate is $0.48M (-79.1% Y/Y).
Over the last 1 year, CAPR has beaten EPS estimates 100% of the time and has beaten revenue estimates 100% of the time.
Over the last 3 months, EPS estimates have seen 0 upward revisions and 5 downward. Revenue estimates have seen 0 upward revisions and 2 downward.

More on Capricor Therapeutics, Inc.

Capricor: Post-CRL Path To DMD Cardiomyopathy Approval In 2026
Capricor Therapeutics: A Buy Ahead Of Phase 3 Topline And Clarified Regulatory Pathway
Capricor Therapeutics, Inc. (CAPR) DMD Program Update Call (Transcript)
Capricor gains as FDA mulls ‘regulatory flexibility’ for lead asset
Capricor Therapeutics, Inc. Q2 2025 Earnings Preview

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。